HUE025731T2 - TCR-NCK kölcsönhatás által mediált betegségek kezelésében hasznos kromonszármazékok - Google Patents

TCR-NCK kölcsönhatás által mediált betegségek kezelésében hasznos kromonszármazékok Download PDF

Info

Publication number
HUE025731T2
HUE025731T2 HUE11828172A HUE11828172A HUE025731T2 HU E025731 T2 HUE025731 T2 HU E025731T2 HU E11828172 A HUE11828172 A HU E11828172A HU E11828172 A HUE11828172 A HU E11828172A HU E025731 T2 HUE025731 T2 HU E025731T2
Authority
HU
Hungary
Prior art keywords
alkyl
formula
compounds
halogen
independently represents
Prior art date
Application number
HUE11828172A
Other languages
English (en)
Inventor
Sanchez Balbino Jose Alarcon
Peypoch Angel Messeguer
De Leon Antonio Morreale
Revuelta Aldo Jorge Borroto
Rojo Irene Azahara Arellano
Requena Almudena Perona
Romero Esther Carrasco
Original Assignee
Consejo Superior De Investig Cientificas (Csic)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consejo Superior De Investig Cientificas (Csic) filed Critical Consejo Superior De Investig Cientificas (Csic)
Publication of HUE025731T2 publication Critical patent/HUE025731T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)

Claims (6)

SZABADALMI KÏÊ^VTONTÛK
1, Az 1 képlet seesMl vegyöleí:
vagy Misnek egy sója, alsók ïBÎÂgyâk Üj: jeleotése egystsástöl íSggettoSl hidrogén, alksi, C^aikenil, C2,< aiknol, hsöroxil. CM alkokll, alkoxí-Sj^alksi fsiaío-CHaltól,. tóítasii-C.^ aíkü, eisRO:--ío:yi sikít, hatog&amp;b -Cbb C>2; B- jeleííissa egy»}áSí»í iígg^lesül CMdM^teU^^xMíi w® balogéig €ví jelentése telített vagy részbesy lelkesen, 5 vagy 6 tagú, osorsodkfeso» festeroeikhss, smày a msfíefetóla töbísí ressséfeeiî béelylk.i^^toésïe HA ly-aiofeion kemætôî kapoaoSsBIIk,,aboi a í.’ys a M, 0<S » közit! vÄSÄiöA ! vagy 2 Sgteföäkssftöt tanalssaaa shot a gyűrű egy vagy Äb C~ vagy S-atoroja CO- SO<- vagy Skí,-csoporuíkkű leket ökiÄvss és ahöt Cy, adott esëïN®egy vagy több B<f-«sbpsAiai szHbs2*ltaá% misdets €yg jelesbése egysoastsi :Égget!ehtó egy $4 ®φ aromás gysirü, amely bármely readelkezesre élló C- vagy M-Atomos* teesÄ fcsfsesoíédhat sí «leírná többi részéhez* alisl 1¾¾ Mit ésölheo «gyesölhet egy hatboeíklnsas vagy· heterociklusos, tellett, részben iektetless vagy aromás, $ vágy é tegb; győrit vél, alsói a 1¾¾ összesest Ι·4 hoteroatorstoí tasáslmazhat: hl, Ο Μ B Maül választva, isitől a, győri egy vagy több €~ vagy S-af«a$a &amp;ö~ SÖ~ vagy Sö^esoporiokbä fehet oxidálva és tÉol Rabtól* esetben egy vagy több ^assoporttal szssbMttöőÍt;; iXikidögylk 1L jelentése egymástól függetlenül €·,.., alkll, ffei aíkenil, Ο,..; alkinií, hldrodb €·,.,: alkoscíl, Cí^atei-Cfaslkík hssio-Ct-otlkil, IóÖíoxMIm alksi, ciaíso-CM alkíl, halogén, -CN vagy -NO,:; s jelentése Ö-A; és m jelentése i.
2, Ass L Igénypont szerinti vegylist ahol stbndygyík B; jelentése egymástól 'fbgj^ÖéAft! 'fci&amp;ög#* 614aM· vagy Oy?.
3, Az 1. vagy a 2. tgésiypont szerinti vegyit let, also! Gyä jelentése az alábbi «söpöri:
4 Az í-3, igéaypom:# bármelyike szeriotl vegyült ahoi Âésgyik Cy;. jeiesrtéss egymMAI ikggerieoiri iésil mgy égy 5 vagy 4 U0 arI» gyárit, arbeiy s moiiíkoia titttf 3#x#ez bármelyik reodélkezésre il® G· vagy bt-atoe» tees^Slkapesoiöiiisk shot a Cys t vágy 2 ® és: S köékt választva, aboi a egy vagy több €- vagy feaiomja CO- SO- vagy SOrésopertokká í#«i oxidálva &amp; ahoi Cy2 adok oseíhaa: öEk vagy iöbö Rrssopötítai saabstritoait.
5, Az 1-4. igénypontok bármelyike szerbit s vegyidet, ahol mindegyik R4 jelentése egymástól blggetíemd CM aiklt. hidroxil. C,, aikoxii, lmlo-C^^alki!, hldtt)xi-C;.4a!kd vagy balogé«,
6. Az i -5. igénypernek hat wíyite-.sæesrMï-sf«^CHeí;_-afea! n jáiöBíese 8 vagy L λ Gyógyszerészeti készítmény* amely tailaintazza: az 1-d, Igénypontok MrnmJy&amp;e szerinti 1 kégietti vegyöte vagy ennek egy gyógyszerészeileg eiibgádháió Sóját és egy vagy több gyógyszerészetileg segédanyagok U. Μ I fgéoypoaiök bármelyike 'm&amp;W$ í kégfetti végytilet vagy etípék egy gyégys^eí-ésáetüeg eltagadható s&amp;Í&amp;ss Trilmíocltákkm llvlt t#ÍÍ köícáisfcpis: Hág "fáiéit fcsfegsét 'taæælésèbiia tdrtënë tslkaltrmxäsfa, ahol a beiepâg a következek közül választóit: oom»ap4antátoo--kslőkődés, rheumatoid arthritis* arthritis psoriatica,. psoriasis, í-es ligásé diabetes, diabetes sxovôdméhp,, sclerosis tKiiäiipiess» szisztémás lapos erythematosus, atoplás: dermáritis, tmst sepk álat közvetítőd átfegils teakeíák, jétskaemiák, lyntphopÄ ég s leukaemsákkái ás lymphtboKäkkal Osszeiíggó thr«mboemboi.iés és alietgias sédvödétéítyek. 4 Az Llgárypoái szerintii képlet® vegyidet előállítási eljárása, aoteiy gkövéikezöke; tattairoazza: (a! H képlehk vegylileit resgáltadisa Hl képleté vegvldedel
akol:Eh % %yCíyo:« és :Jrt|etm3téss a2 i íg&amp;tpöSíbán leírjak szerinti; és/vagy (b)'aa I képiéit vegyüet egy Étt I képistíí vegydlesté való áiaiakftása egy vagy több iepésbetk
HUE11828172A 2010-09-28 2011-07-08 TCR-NCK kölcsönhatás által mediált betegségek kezelésében hasznos kromonszármazékok HUE025731T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201031437A ES2379242B1 (es) 2010-09-28 2010-09-28 Derivados de cromeno.

Publications (1)

Publication Number Publication Date
HUE025731T2 true HUE025731T2 (hu) 2016-05-30

Family

ID=45892008

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE11828172A HUE025731T2 (hu) 2010-09-28 2011-07-08 TCR-NCK kölcsönhatás által mediált betegségek kezelésében hasznos kromonszármazékok

Country Status (17)

Country Link
US (1) US9120764B2 (hu)
EP (1) EP2623503B1 (hu)
JP (1) JP5894164B2 (hu)
KR (1) KR101800919B1 (hu)
CN (1) CN103189367B (hu)
AU (1) AU2011310078B2 (hu)
BR (1) BR112013007073B1 (hu)
CA (1) CA2813144C (hu)
DK (1) DK2623503T3 (hu)
ES (1) ES2379242B1 (hu)
HK (1) HK1186727A1 (hu)
HR (1) HRP20151378T1 (hu)
HU (1) HUE025731T2 (hu)
MX (1) MX342960B (hu)
PL (1) PL2623503T3 (hu)
PT (1) PT2623503E (hu)
WO (1) WO2012042078A1 (hu)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014336153A1 (en) * 2013-10-17 2016-04-28 AbbVie Deutschland GmbH & Co. KG Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy
ES2534336B1 (es) * 2013-10-18 2016-01-28 Artax Biopharma Inc. Derivados de cromeno como inhibidores de la interacción TCR-Nck
ES2534318B1 (es) * 2013-10-18 2016-01-28 Artax Biopharma Inc. Derivados de cromeno sustituidos por alcóxido como inhibidores de la interacción TCR-Nck
US9968604B2 (en) 2015-04-16 2018-05-15 Chiesi Farmaceutici S.P.A. Chromene derivatives as phoshoinositide 3-kinases inhibitors
CN117304157A (zh) * 2018-02-27 2023-12-29 阿塔克斯生物制药有限公司 作为tcr-nck相互作用的抑制剂的色烯衍生物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002008217A2 (en) * 2000-07-21 2002-01-31 Chugai Seiyaku Kabushiki Kaisha COUMARIN DERIVATIVES USEFUL AS TNFα INHIBITORS
CA2547518A1 (en) * 2003-12-12 2005-06-30 Wyeth Quinolines useful in treating cardiovascular disease
CA2938241A1 (en) * 2006-07-06 2008-01-10 Cytovia, Inc. Substituted 4-aryl-chromene as activator of caspases and inducer of apoptosis and as antivascular agent and the use thereof
ES2331451B1 (es) 2008-06-30 2010-10-21 Consejo Superior De Investigaciones Cientificas (Csic) Inmunosupresor basado en la interrupcion de la interaccion tcr-nck.
BRPI0922135B1 (pt) * 2008-12-05 2021-07-13 Astellas Pharma Inc Composto de 2h-cromeno ou um sal do mesmo, composição farmacêutica compreendendo dito composto e uso do mesmo para prevenir ou tratar uma doença induzida por infiltração de linfócito indesejável associada com s1p1

Also Published As

Publication number Publication date
BR112013007073B1 (pt) 2021-11-16
PL2623503T3 (pl) 2016-04-29
US9120764B2 (en) 2015-09-01
CA2813144C (en) 2018-10-30
ES2379242B1 (es) 2013-03-04
BR112013007073A2 (pt) 2020-04-28
KR101800919B1 (ko) 2017-11-23
HK1186727A1 (zh) 2014-07-04
CN103189367A (zh) 2013-07-03
DK2623503T3 (en) 2016-01-11
ES2379242A1 (es) 2012-04-24
JP5894164B2 (ja) 2016-03-23
EP2623503B1 (en) 2015-09-23
MX342960B (es) 2016-10-18
KR20130141481A (ko) 2013-12-26
MX2013003498A (es) 2013-05-20
CN103189367B (zh) 2016-06-08
JP2013537899A (ja) 2013-10-07
RU2013117924A (ru) 2014-11-10
EP2623503A4 (en) 2014-03-05
HRP20151378T1 (hr) 2016-01-15
AU2011310078B2 (en) 2016-12-15
CA2813144A1 (en) 2012-04-05
WO2012042078A1 (es) 2012-04-05
EP2623503A1 (en) 2013-08-07
US20140005247A1 (en) 2014-01-02
AU2011310078A1 (en) 2013-04-11
PT2623503E (pt) 2016-01-26

Similar Documents

Publication Publication Date Title
CA3037986C (en) Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
JP7021394B2 (ja) ニューロキニン－１受容体アンタゴニストとしての化合物およびその使用
KR20120117905A (ko) 프로테아좀 활성을 향상시키는 조성물 및 방법
UA74850C2 (en) Amide derivatives as nmda receptor antagonists
CA2770932C (en) Substituted n-phenyl-1-(4-pyridinyl)-1h-pyrazol-3-amines
EP2513114A1 (en) Pyrrolo[2,3-d]pyrimidine compounds
DE102006029447A1 (de) Oxo-substituierte Imidazo[1,2b]pyridazine, deren Herstellung und Verwendung als Arzneimittel
TW200911254A (en) Oxadiazole derivatives and their use as metabotropic glutamate receptor potentiators-842
WO2014163147A1 (ja) ピラゾロキノリン誘導体の塩およびその結晶
JP6322275B2 (ja) ヤヌスキナーゼ阻害剤としてのｎ−（２−シアノヘテロシクリル）ピラゾロピリドン
AU2011310078B2 (en) Chromene derivatives
CN106573907A (zh) 新颖的喹啉衍生物及其用于神经退化性疾病的用途
JP7138768B2 (ja) ジメチルホスフィンオキシド化合物
JP7263659B2 (ja) カルボン酸基を含む窒素含有ベンゾ複素環化合物、その調製方法及び使用
JP5726321B2 (ja) オキサゾロ［５，４−ｂ］ピリジン−５−イル化合物および癌治療へのその使用
RU2574164C2 (ru) Производные хромена
CA3102903A1 (en) Oga inhibitor compounds
GB2610812A (en) Novel compounds
CA3207452A1 (en) Vmat2 inhibitors and methods of use
JP2010534231A (ja) デュシェンヌ型筋ジストロフィーを治療するための化合物
EP2315762A2 (en) Fluoro-substituted 3,4-diaryl-4,5-dihydro-1h-pyrazole-1-carboxamidine derivatives having cb1-antagonistic activity